Form 4: NEOGENOMICS Executive Sells Shares Under 10b5-1 Plan

Alicia C. Olivo, EVP, GC & Business Development at NEOGENOMICS INC, sold 4,918 shares of common stock for $10 per share under a pre-arranged trading plan.

Summary

• Alicia C. Olivo, Executive Vice President, General Counsel, and Business Development for NEOGENOMICS INC (NEO), reported a disposition of company common stock.
• On October 16, 2025, Ms. Olivo disposed of 4,918 shares of NEOGENOMICS INC common stock at a price of $10 per share.
• This transaction was executed pursuant to a Rule 10b5-1 trading plan, which allows insiders to set up a pre-scheduled plan to sell shares to avoid accusations of insider trading.
• Following this transaction, Ms. Olivo directly beneficially owns 43,022 shares of common stock.
• The filing also details various derivative securities beneficially owned, including numerous stock options with exercise prices ranging from $9.45 to $48.99, and restricted and performance stock units.

Sentiment

Score: 5

Explanation: Neutral. This is a routine insider transaction filing under a pre-arranged 10b5-1 plan, which is generally considered a neutral event. It does not indicate positive or negative company performance, but rather an executive's personal financial planning.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled transaction rather than an immediate reaction to new, non-public information.
• Ms. Olivo retains a significant beneficial ownership of 43,022 common shares and a substantial number of derivative securities, aligning her interests with shareholders.

Negatives

• An executive selling shares, even under a 10b5-1 plan, can sometimes be perceived negatively by the market, as it reduces their direct equity stake.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance beyond the scheduled vesting of equity awards and the future transaction date of the reported sale.

Management Comments

• The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

Industry Context

This Form 4 filing is a routine disclosure of an insider stock transaction and does not provide information directly related to broader industry trends or competitive landscape. It reflects an individual executive's equity management within the biotechnology/diagnostics sector.

Comparison to Industry Standards

• This filing is a standard regulatory disclosure for insider transactions. Without specific financial or operational results, a direct comparison to industry benchmarks or competitor performance is not applicable.
• The use of a Rule 10b5-1 plan is a common practice for executives to manage their equity holdings in a compliant manner, aligning with corporate governance best practices.

Stakeholder Impact

• Shareholders: The sale of shares by an executive could be interpreted in various ways, but the use of a 10b5-1 plan mitigates concerns about opportunistic selling. The executive still holds a significant number of shares and derivative instruments, indicating continued alignment with shareholder interests.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• Continued vesting of various stock options, restricted stock units, and performance stock units for Alicia C. Olivo according to their respective schedules.
• Potential future sales or acquisitions by Ms. Olivo, which would be reported in subsequent Form 4 filings.

Key Dates

Recommendation

This Form 4 filing reports a pre-scheduled insider sale under a Rule 10b5-1 plan, which is a routine event for executives managing their personal finances. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The executive retains substantial equity holdings, indicating continued alignment with shareholder interests. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present a compelling reason to buy or sell.

Keywords

NEOGENOMICS, NEO, Form 4, Insider Trading, Stock Sale, Alicia C. Olivo, 10b5-1 Plan, Executive Compensation, Equity Ownership